Company profile: Vitae Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies, building a portfolio of novel, best-in-class small molecules and biologics addressing significant unmet needs, including chronic kidney disease, diabetes, atherosclerosis, and Alzheimer’s. Programs span immunology, oncology, neuroscience, eye care, aesthetics, and patient access and support.
Products and services
- Immunology: Architects targeted oral therapies and biologics for Crohn’s disease, ulcerative colitis, psoriasis, atopic dermatitis, and rheumatoid arthritis
- Small-molecule
- Neuroscience: Engineers therapies for neurodegenerative and psychiatric disorders, including Alzheimer’s, Parkinson’s, bipolar disorder, and schizophrenia, utilizing novel small molecule compounds
- Clinical-stage
- Oncology: Develops biologics, cell therapies, and small molecules that target tumor cell processes across hematologic malignancies and solid tumors
- Cell-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vitae Pharmaceuticals
Elcelyx
HQ: United States
Website
- Description: Provider of nutrient sensing-based products in development for weight management and obesity-related metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elcelyx company profile →
Fractyl Health
HQ: United States
Website
- Description: Provider of curative therapies for metabolic diseases, including Revita, a therapy designed to modify duodenal dysfunction via hydrothermal ablation to restore metabolic health, and Rejuva, a preclinical AAV gene therapy platform aimed at improving islet function for long-term remission of T2D and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fractyl Health company profile →
CytoTools
HQ: Germany
Website
- Description: Provider of unique biotechnology therapies derived from fundamental biology research on cell growth and programmed cell death, designed to treat the causes of disease rather than the symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoTools company profile →
Sano
HQ: United States
Website
- Description: Provider of a small wearable sensor that continuously captures and transmits blood chemistry data to virtually any device and liberates this data to a third-party development and analytical platform called the 'API for the bloodstream'.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sano company profile →
Medesis Pharma
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development leveraging AONYS, a buccal micro-emulsion platform enabling delivery of water-soluble actives across the blood-brain barrier, to develop orally administered candidates addressing unmet needs, including Nanolithium for Alzheimer's, NanoManganese for radiotherapy, NU01/NU02 for plutonium/cesium decorporation, and P42 for Huntington's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medesis Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vitae Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vitae Pharmaceuticals
2.2 - Growth funds investing in similar companies to Vitae Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vitae Pharmaceuticals
4.2 - Public trading comparable groups for Vitae Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →